Sandra Shotwell

Sandra Shotwell is the current Director at Oregon Bioscience. Sandra has also co-founded ELEX BIOTECH, INC and is currently the Board Chair. Elex Biotech Inc is a drug discovery and development company focused on first-in-class new compounds for the treatment of arrhythmia and heart failure. Sandra has also been a Board Member for Veana Therapeutics Inc for 2 years now. Veana Therapeutics is a clinical stage research and development biotechnology company whose primary mission is to develop safer, more effective immunotherapies that will improve and extend the lives of the many people affected by the deadly disease of cancer. Lastly, Sandra is also the Principal for Alta Biomedical Group. Alta Biomedical Group is a technology commercialization consulting firm based in Portland, Oregon that serves U.S. and international clients, including companies, research institutions, non-profit organizations and government agencies. Alta Biomedical provides services broadly in innovation management, including policy development, technology assessment, valuation, marketing, licensing, collaboration, business development strategy and management consulting.

Sandra Shotwell has a B.A. from Princeton University in Physiological Psychology, a Ph.D. from the California Institute of Technology in Biology, and a postdoctoral from Stanford University School of Medicine in Neurobiology. Sandra co-founded the local chapter of Association for Women in Science while at Stanford.